Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Doxorubicin hydrochloride by Skinject for Basal Cell Carcinoma (Basal Cell Epithelioma): Likelihood of Approval
Doxorubicin hydrochloride is under clinical development by Skinject and currently in Phase II for Basal Cell Carcinoma (Basal Cell Epithelioma)....